The CRISPR patent landscape keeps on steadily growing, with an additional 70 patent publications last month. We have now monitored more than 1400 patent families in our latest CRISPR patent analytics data set. In the past few weeks, our patent landscape data was quoted in the WIPO magazine coverage of CRISPR, while our expert Fabien Palazzoli had the opportunity to present his latest findings at the Cell Line Development and Engineering conference in Amsterdam and to Deftech in Switzerland.
The past 24 hours have brought new light and significant moves in the complex CRISPR patent landscape.
First (that was in European time zone!), our CRISPR expert Fabien Palazzoli celebrated the 1000th CRISPR patent family extraction out of the worldwide published patent databases. Our next monthly update will actually feature more than 1050 classified and categorized CRISPR patent families – more than 10 times the initial set of our first landscape release back in summer 2014!
Earlier this month, we were interviewed by The Scientist regarding the side inventorship dispute between Feng Zhang and Luciano Marraffini on some of the Broad patent applications. Public registers at the USPTO, WIPO and the EPO expose further details of the otherwise un-publicized legal battles for invention ownership between their employers (the Broad Institute of Harvard and MIT and Rockfeller University), back from the 2012-2013 early filings.
For the first quarter of 2016, we have added another 105 patent families to our CRISPR patent monitoring set. The CRISPR patent landscape keeps on growing steadily, with on average one new CRISPR patent family publication every day.
Less licensing deals have been announced in the past few months, as the whole industry is watching for USPTO updates on the PTAB interference between two of the pioneering patent filings. More qualitative financial analysts are also now monitoring the outcome of this dispute, after the first successful CRISPR IPO (NASDAQ:EDIT) by Editas, a licensee of the pioneering Broad Institute patents, and the early April announcement of its own IPO filing by rival Intellia, a licensee of the pioneering University of California patent. In Europe, the CRISPR patent landscape is just as uncertain, with multiple (many anonymous – “strawman”) oppositions filed on the first granted patents.
While the uncertainty surrounding the licensing of the core technology patents is getting most media and business attention currently, the next rounds are already taking shape behind this main scene, with near 600 silent patent families claiming their own exclusive share of technology improvements, design-around attempts, and a myriad of specific application developments. There will be further disputes, settlements, and maybe even patent pools in the CRISPR era. The whole data is there, in multiple patent offices and databases – at IPStudies, we search, retrieve, sort and classify this data set to facilitate the CRISPR technology and competition watch for our customers: for more information on our patent landscape and patent monitoring services, check our CRISPR patent analytics offering or send us your inquiry through our contact form.